Xu, Yun
Peng, Hewei
Su, Guangjian
Cheng, Yanming
Guo, Qiaojuan
Guo, Lanyan
Peng, Xian-E
Ke, Jiangfeng
Funding for this research was provided by:
the Natural Science Foundation of Fujian Province (No. 2019Y0061)
National Clinical Key Specialty Construction Program, and Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy (No. 2020Y2012, No. 2020Y2012)
Article History
Received: 22 November 2022
Accepted: 3 August 2023
First Online: 25 August 2023
Declarations
:
: This study was approved by the ethics committee of Fujian Cancer Hospital. Written informed consent was obtained from all patients.
: All authors consent to the publication of the manuscript.
: The authors have no conflicts of interest with respect to the work presented in this study.